| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Fenthion (the non-deuterated parent compound) targets the enzyme acetylcholinesterase (AChE) in the nervous system of insects. It acts as a cholinesterase inhibitor, preventing the breakdown of the neurotransmitter acetylcholine, leading to accumulation at synapses, continuous nerve firing, paralysis, and eventual death of the target pest. Fenthion is metabolically activated to fenthion oxygen analogue (fenthoxone), which is a more potent AChE inhibitor. The deuterium-labeled fenthion-d6 has the same target but is used as an analytical standard, not a pesticide.
|
|---|---|
| ln Vitro |
In vitro activity of fenthion-d6 as a stable isotope-labeled standard is not characterized separately from the parent compound, as it is used primarily for quantification. The parent compound fenthion inhibits cholinesterase activity. The deuterium label does not significantly alter the physicochemical properties for analytical purposes, but may influence metabolic stability due to the kinetic isotope effect in some metabolic pathways. However, for quantification purposes, it is assumed to behave identically to unlabeled fenthion.
|
| ln Vivo |
In vivo, the parent compound fenthion is absorbed, distributed, metabolized, and excreted in animals and plants. In rats, fenthion is readily oxidized to fenthion oxygen analogue, and fenthion sulfoxide and sulfone are major metabolites. Recovery of fenthion in pig excreta reached 95% in males and 91% in females after 54 hours, with 86-87% of dose recovered in urine, 81-84% within the first 24 hours. Residues are not stored in tissues. Fenthion-d6 is not administered in vivo for therapeutic purposes.
|
| Enzyme Assay |
Receptor/enzyme binding assays are not performed for isotope-labeled standards like fenthion-d6. For the parent compound fenthion, cholinesterase inhibition assays can be conducted using acetylcholinesterase enzyme (human or insect origin) and chromogenic substrates (e.g., acetylthiocholine with Ellman's reagent). The compound is incubated with enzyme, and activity is measured spectrophotometrically at 412 nm. Fenthion-d6 is used as an internal standard in sample preparation for these assays to quantify fenthion concentrations.
|
| Cell Assay |
Cell-based assays for fenthion typically use neuronal cell lines (e.g., SH-SY5Y neuroblastoma cells) to assess cytotoxicity and AChE inhibition. Cells are exposed to fenthion (1-500 microM) for 24-72 hours, cell viability is measured by MTT assay, and AChE activity is determined by colorimetric assay. However, fenthion-d6 is not used in these assays as a treatment compound; it serves as an analytical standard for sample preparation prior to LC-MS analysis of fenthion concentrations in cell lysates or culture media.
|
| Animal Protocol |
In vivo animal metabolism studies for fenthion: Rats, pigs, goats, or cows are administered radiolabeled or non-labeled fenthion (usually via oral gavage at 1-20 mg/kg). Urine, feces, milk, and tissues are collected at various time points (0-72 hours or longer). Fenthion-d6 is added as an internal standard to these biological samples prior to extraction and LC-MS/MS analysis to accurately quantify parent compound and metabolite concentrations. The deuterated standard corrects for matrix effects and extraction efficiency.
|
| ADME/Pharmacokinetics |
Fenthion-d6 is used as an internal standard in LC-MS/MS quantification of fenthion and its metabolites. The parent compound fenthion has a plasma half-life in rodents of approximately 6-12 hours. Metabolism generally commences with desulphuration of the thiophosphoric ester portion to yield the oxon analogue (fenthoxone), followed by further oxidation to sulfoxide and sulfone metabolites. These metabolites are more water-soluble and are excreted primarily in urine (80-85% of dose within 24 hours in rats). Fenthion-d6 has the same PK properties as the parent compound for analytical purposes.
|
| Toxicity/Toxicokinetics |
Fenthion (the parent compound) exhibits significant toxicity as an acetylcholinesterase inhibitor. Acute toxicity symptoms include salivation, lacrimation, urination, defecation, gastrointestinal distress, muscle fasciculations, respiratory depression, and convulsions. The oral LD50 in rats is approximately 215-615 mg/kg. Chronic exposure may cause neurotoxicity. Fenthion-d6 has the same toxicological profile as the parent compound but is handled at much lower concentrations as an analytical standard with appropriate safety precautions including fume hood use and personal protective equipment.
|
| References |
[1]. Zhengzhong Lin, et al. Spectrophotometric detection of fenthion in foods after extraction by magnetic zirconia. Appl Opt. 2020 Apr 1;59(10):3043-3048.
[2]. Jonghwa Lee, et al. Simultaneous Analysis of Fenthion and Its Five Metabolites in Produce Using Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry. Molecules. 2020 Apr 22;25(8):1938. |
| Additional Infomation |
Fenthion-d6 is not a drug and has no clinical applications or regulatory approval for therapeutic use. It is a stable isotope-labeled analytical standard (deuterium-labeled) for research and quality control purposes. The product is used for method development, method validation (AMV), and quality control (QC) applications for Abbreviated New Drug Application (ANDA) or during commercial production of analytical reference standards. Fenthion is an organophosphate pesticide; fenthion-d6 aids in its accurate detection and quantification in environmental, food, and biological samples.
|
| Molecular Formula |
C10H9D6O3PS2
|
|---|---|
| Molecular Weight |
284.37
|
| Exact Mass |
284.057
|
| CAS # |
1189662-83-6
|
| PubChem CID |
45039252
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
330.0±52.0 °C at 760 mmHg
|
| Flash Point |
153.4±30.7 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.565
|
| LogP |
3.21
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
16
|
| Complexity |
254
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C)C1C=CC(=CC=1C)OP(OC([2H])([2H])[2H])(OC([2H])([2H])[2H])=S
|
| InChi Key |
PNVJTZOFSHSLTO-XERRXZQWSA-N
|
| InChi Code |
InChI=1S/C10H15O3PS2/c1-8-7-9(5-6-10(8)16-4)13-14(15,11-2)12-3/h5-7H,1-4H3/i2D3,3D3
|
| Chemical Name |
(3-methyl-4-methylsulfanylphenoxy)-sulfanylidene-bis(trideuteriomethoxy)-λ5-phosphane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5165 mL | 17.5827 mL | 35.1655 mL | |
| 5 mM | 0.7033 mL | 3.5165 mL | 7.0331 mL | |
| 10 mM | 0.3517 mL | 1.7583 mL | 3.5165 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
